PUGLISI, FRANCESCO
PUGLISI, FRANCESCO
Universita' degli Studi di MILANO
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
2026 G. Curigliano, X. Hu, R. Dent, K. Yonemori, C.H. Barrios, J. Pierga, F. Puglisi, J. Ferrero, K.H. Jung, N.A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
2024 A. Zambelli, L. Cortesi, M. Gaudio, G. Arpino, G. Bianchini, F. Caruso, S. Cinieri, G. Curigliano, L. Del Mastro, S. De Placido, A. Fabi, L. Fortunato, D. Generali, A. Gennari, S. Gori, G. Grandi, V. Guarneri, M. Klinger, L. Livi, C. Marchio, I. Palumbo, P. Panizza, G. Pravettoni, G. Pruneri, F. Puglisi, A. Sapino, C. Tinterri, D. Turchetti, M. De Laurentiis
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
2023 F. Miglietta, A. Fabi, D. Generali, M.V. Dieci, G. Arpino, G. Bianchini, S. Cinieri, P.F. Conte, G. Curigliano, M. De Laurentis, L. Del Mastro, S. De Placido, A. Gennari, F. Puglisi, A. Zambelli, F. Perrone, V. Guarneri
Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance
2022 C. Corvaja, B. Taurelli Salimbeni, E. Nicolo, F. Puglisi, G. Curigliano
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
2022 A. Fabi, G. Buono, E. Bria, G. Bianchini, G. Curigliano, M. De Laurentiis, S. De Placido, L. Del Mastro, V. Guarneri, D. Generali, L. Livi, V. Lorusso, F. Montemurro, F. Puglisi, P. Vigneri, A. Zambelli, G. Arpino